KRAS and neoplasm: Finally, in PDX models derived from a KRAS-mutant, chemotherapy-resistant CRC case, RGS decreased subcutaneous tumor growth more effectively than the combination of 5-FU, irinotecan/oxaliplatin, and bevacizumab treatment, which is the first-line clinical treatment for KRAS-mutant mCRC patients.